They usually diminish as the body adjusts, but in some cases, they can be persistent and severe enough to require discontinuation of the medication
In clinical trials, people who took semaglutide lost an average of 15 to 20% of their body weight over the course of one year, which is a remarkable result
Clinical trials show that tirzepatide, a dual GLP-1 and GIP receptor agonist, produces weight loss signals earlier in many patients compared to single-mechanism GLP-1 drugs, though individual response depends on metabolism and genetic sensitivity to these pathways
How quickly do these changes develop
A combination of peptides referenced in laboratory research literature
Since then, a number of studies have also been conducted in human primary hepatocytes, providing evidence for the direct effect of GLP-1 binding with GLP-1R in hepatocytes on reducing liver lipids [64]